MKI67 and neoplasm: Research has shown that tumor-bearing mice treated intraperitoneally with JQ1 at a dose of 50 mg/kg/day or 25 mg/kg dosed twice per day exhibited significant tumor growth inhibition and regression in subcutaneous HCCLM3 xenograft models, which correlated with a decrease in Ki-67 positive tumor cells (Li et al., 2016).